Business Context and Reporting Period
Company: Aligos Therapeutics, Inc. (ALGS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Aligos is a clinical-stage biotechnology company developing novel therapeutics for liver diseases (Chronic Hepatitis B, MASH) and viral infections (Coronavirus). The company has no products approved for commercial sale and has incurred significant losses since inception. It operates as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Total Revenue | $3,945 | $15,529 |
| Net Loss | $(131,211) | $(87,679) |
| Research & Development Expenses | $70,269 | $73,040 |
| General & Administrative Expenses | $22,830 | $30,616 |
| Cash, Cash Equivalents & Investments (Dec 31, 2024) | $56,939 | $135,774 |
| Accumulated Deficit (Dec 31, 2024) | $(618,008) | $(486,797) |
| Warrant Liability (Dec 31, 2024) | $72,367 | $27,596 |
Note: Revenue consists of collaboration revenue ($0.3M) and customer contract revenue ($3.6M). The Net Loss includes a non-cash charge of $46.1M related to the change in fair value of common warrants.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by approximately 75% year-over-year. Collaboration revenue dropped 96% due to the completion of the Merck collaboration agreement in May 2024. Customer revenue decreased 42% primarily due to the timing of the Amoytop agreement signed in 2023.
- Increased Net Loss: Net loss increased by 50% to $131.2 million. This was driven primarily by a $44.0 million increase in the non-cash change in fair value of common warrants (from $2.2M expense in 2023 to $46.1M in 2024).
- Expense Reductions: Operating expenses decreased by 10% to $93.1 million. General and Administrative expenses fell 25% due to reduced legal/IP spend and lower stock-based compensation. R&D expenses decreased 4% despite increased third-party clinical costs, offset by lower employee-related costs.
- Liquidity Position: Cash and investments decreased significantly from $135.8 million in 2023 to $56.9 million in 2024, reflecting a net cash burn of $98.7 million for the year.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Management expects to incur significant expenses and operating losses for the foreseeable future. As of December 31, 2024, the company had $56.9 million in cash. Following a subsequent event (February 2025 private placement raising $105.0 million), management believes it can fund operations for at least 12 months from the filing date. The company anticipates needing substantial additional financing to advance clinical trials and commercialize products.
Key Pipeline Updates:
- ALG-000184 (Chronic HBV): Phase 1 data showed sustained HBV DNA suppression. Phase 2 enabling activities are ongoing, with a Phase 2 study expected to begin in mid-2025.
- ALG-055009 (MASH): Phase 2a (HERALD) study met its primary endpoint with statistically significant reductions in liver fat. Phase 2b enabling activities are underway.
- ALG-097558 (Coronavirus): Phase 1 completed; currently in clinical trials for high-risk COVID-19 patients. Development is partially funded by NIH/NIAID contracts totaling approximately $13.8 million.
Material Risks:
- Need for Capital: Failure to obtain additional financing could force delays or termination of development programs.
- Warrant Liability Volatility: The company carries a significant warrant liability ($72.4M) subject to fair value remeasurement, which creates volatility in reported net loss.
- Development Risk: No products are approved; clinical trials may fail to demonstrate efficacy or safety.
- Collaboration Termination: The Merck collaboration was terminated in 2024, reducing near-term revenue visibility.
Investor Verification Checklist
- Cash Runway: Verify the impact of the February 2025 $105M financing on the company's ability to fund operations through 2025 and into 2026.
- Warrant Liability Impact: Assess the sensitivity of the $72.4M warrant liability to stock price fluctuations and its effect on future reported earnings.
- Revenue Sustainability: Confirm the status of the Amoytop and ADCT agreements to understand the trajectory of the declining revenue stream.
- Clinical Milestones: Monitor the initiation of the Phase 2 study for ALG-000184 (expected mid-2025) and the design of the Phase 2b study for ALG-055009.
- Government Funding: Track the disbursement and utilization of the ~$13.8M in NIH/NIAID funds for the coronavirus program.